HCA Healthcare, Inc. (HCA) $406.59
HCA Healthcare is flashing overbought signals, testing the patience of bulls despite strong institutional backing.
52-wk High $556.52
📌 Investment Snapshot
- Price: $406.59 | P/E: 14.0x
- Latest Q Revenue: $19.11B | EPS: $7.15
- Catalyst: Strong institutional accumulation
- Consensus Target: $493.52 (+21.4% upside)
The stock’s RSI at 72.1 signals an overextended rally, suggesting a cooling-off period is imminent. Avoid chasing the current momentum until the price consolidates closer to the $390 support level.
| 📍 Entry Zone | $385.00 or below | 🛑 Stop-Loss | $365.00 |
| 📋 Adjust If | Price reclaims $425 with high volume | ||
The Investment Case — Why Now?
HCA remains a dominant force in medical care facilities, yet the recent 9.1% monthly surge leaves little margin for error. The market is pricing in perfection ahead of the upcoming earnings print, creating a binary risk profile for new entrants.
While the technical confluence score of 80/100 validates the underlying strength, the current RSI reading forces a cautious stance. We prefer waiting for the inevitable mean reversion to capture a more favorable risk-reward ratio.
🤔 Does the current 72.1 RSI reading deter your entry, or do you view this as a breakout confirmation?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $385.24 on 2026-06-11
SMA50 ($399.33) is acting as immediate support, while the stock trades well below the SMA200 ($458.58), highlighting a long-term downtrend recovery.
RSI at 72.1 screams overbought, warning that the recent 9.1% monthly gain lacks sustainable momentum.
The stock sits above the VWAP ($440.25), but the recent liquidity sweeps at $421.35 and $385.24 show active institutional churn.
A bearish FVG zone ($412.46-$419.43) looms overhead, likely acting as a magnet for profit-taking before any further upside.
The confluence score of 80/100 is impressive, yet the overbought condition overrides the bullish setup for a prudent entry.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| HCA | HCA Healthcare | 14.0x |
| SPY | S&P 500 | 21.5x |
| UHS | Universal Health | 16.2x |
| THC | Tenet Healthcare | 18.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $19.11B | $7.15 | +2.7% |
| Q4 2025 | $19.51B | $8.09 | +1.8% |
| Q3 2025 | $19.16B | $6.96 | +3.0% |
| Q2 2025 | $18.61B | $6.83 | +2.5% |
Free Cash Flow remains robust at $0.9B, supporting the aggressive $1.6B buyback program executed in the latest quarter.
Earnings consistency remains a hallmark of HCA, though the market will focus heavily on margin guidance during the upcoming report.
🚀 Growth Drivers — What Moves the Stock
- Operational Efficiency 🟡 Priced In — HCA continues to optimize margins through rigorous cost management and facility utilization.
- Demographic Tailwinds 🟢 Upside Surprise — Aging population trends provide a structural floor for long-term revenue growth.
🤔 With earnings approaching, will HCA maintain its margins, or will rising labor costs erode the bottom line?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 13,363 |
| Vanguard Capital | 10,178 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MARKS MIKE A | CFO | 2026-05-07 | Sale | 3336 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 3.7% | 3.1 |
⚠ Key Risk Factors
~$2B impact
~$1B impact
~$1.5B impact
~$3B impact
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $635.00 | $493.52 | $396.00 | 21 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Barclays | Equal-Weight | $N/A | 2026-07-08 | down |
Analysts remain broadly bullish, yet recent downgrades signal growing caution regarding valuation.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong institutional ownership
- Resilient demographic demand
📊 Base Case
Stable operations with moderate growth.
🐻 Bear Case
- Overextended RSI
- Rising labor costs
🎯 Investor Action Plan — By Profile
Avoid entry until RSI cools below 60.
Wait for a pullback to the $385-$390 support zone.
Maintain existing positions; avoid adding at current overbought levels.
❓ Investor FAQ — People Also Ask
Q: Is HCA a buy right now?
No, the stock is currently overbought with an RSI of 72.1, suggesting a pullback is likely.
Q: What is the key support level?
The $390 level acts as a critical support zone, aligned with recent volume profile activity.
Q: When is the next earnings release?
Earnings are expected in mid-July 2026, which introduces significant volatility risk.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Always perform your own due diligence before investing.
All active positions and their real-time performance are tracked on our Investment Log.
#HCA #Healthcare #StockMarket #Investing #TechnicalAnalysis #WallStreet #Earnings #Stocks